(Q34172223)

English

Proarrhythmia

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

1 reference

Europe PubMed Central

Proarrhythmia. (English)

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

author name string

Naccarelli GV

1

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Wolbrette DL

2

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Luck JC

3

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

publication date

1 March 2001

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Medical Clinics of North America

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

85

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

503-26, xii

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Occurrence of exercise-induced and spontaneous wide complex tachycardia during therapy with flecainide for complex ventricular arrhythmias: a probable proarrhythmic effect

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970324-2

7 January 2021

Proarrhythmic effects of antiarrhythmic drugs during programmed ventricular stimulation in patients without ventricular tachycardia

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970324-2

7 January 2021

Drug therapy for torsade de pointes

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970324-2

7 January 2021

Efficacy and safety of flecainide acetate for atrial tachycardia or fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970324-2

7 January 2021

Clinical types of proarrhythmic response to antiarrhythmic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970324-2

7 January 2021

Amiodarone-induced torsades de pointes

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970324-2

7 January 2021

A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970324-2

7 January 2021

Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970324-2

7 January 2021

Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: the CAPS

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970324-2

7 January 2021

Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970324-2

7 January 2021

Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970324-2

7 January 2021

Flecainide-induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970324-2

7 January 2021

Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970324-2

7 January 2021

Inefficacy and proarrhythmic effects of flecainide and encainide for sustained ventricular tachycardia and ventricular fibrillation.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970324-2

7 January 2021

Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970324-2

7 January 2021

Proarrhythmic responses during electrophysiologic testing

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970324-2

7 January 2021

The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970324-2

7 January 2021

Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970324-2

7 January 2021

Controlled trial of sotalol for one year after myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970324-2

7 January 2021

Late proarrhythmia and understanding the time of occurrence of proarrhythmia

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970324-2

7 January 2021

Safety and risk/benefit analysis of ibutilide for acute conversion of atrial fibrillation/flutter

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970324-2

7 January 2021

Sotalol-induced torsade de pointes

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970324-2

7 January 2021

Short- and long-term experience with flecainide acetate in the management of refractory life-threatening ventricular arrhythmias

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970324-2

7 January 2021

Risk of initiating antiarrhythmic drug therapy for atrial fibrillation in patients admitted to a university hospital

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970324-2

7 January 2021

Clinical characteristics of patients with ventricular fibrillation during antiarrhythmic drug therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970324-2

7 January 2021

Risk factors for the development of proarrhythmic events

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970324-2

7 January 2021

Classification by type of ventricular arrhythmia predicts frequency of adverse cardiac events from flecainide

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970324-2

7 January 2021

Flecainide: its proarrhythmic effect and expected changes on the surface electrocardiogram

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970324-2

7 January 2021

Incidence of proarrhythmic effects from quinidine in the outpatient treatment of benign or potentially lethal ventricular arrhythmias

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970324-2

7 January 2021

Prevalence and characteristics of proarrhythmia from moricizine (Ethmozine)

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970324-2

7 January 2021

Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970324-2

7 January 2021

Reversal of proarrhythmic effects of flecainide acetate and encainide hydrochloride by propranolol

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970324-2

7 January 2021

Adverse effects of amiodarone. Pathogenesis, incidence and management

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970324-2

7 January 2021

Disopyramide-induced ventricular fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970324-2

7 January 2021

"Late" proarrhythmia due to quinidine

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970324-2

7 January 2021

Aggravation of arrhythmia by antiarrhythmic drugs--incidence and predictors

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970324-2

7 January 2021

Aggravation of arrhythmia induced with antiarrhythmic drugs during electrophysiologic testing

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970324-2

7 January 2021

Proarrhythmic potential of moricizine: Strengths and limitations of a data base analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970324-2

7 January 2021

Mortality in patients treated with flecainide and encainide for supraventricular arrhythmias

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970324-2

7 January 2021

Proarrhythmic effects of antiarrhythmic drugs in patients with malignant ventricular arrhythmias evaluated by electrophysiologic testing

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970324-2

7 January 2021

Evaluation of flecainide acetate in the management of patients at high risk of sudden cardiac death

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970324-2

7 January 2021

Drug conversion of nonsustained ventricular tachycardia to sustained ventricular tachycardia during serial electrophysiologic studies: identification of drugs that exacerbate tachycardia and potential mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970324-2

7 January 2021

Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970324-2

7 January 2021

Arrhythmogenic actions of antiarrhythmic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970324-2

7 January 2021

Antiarrhythmic drugs: a possible cause of out-of-hospital cardiac arrest

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970324-2

7 January 2021

QUINIDINE SYNCOPE. PAROXYSMAL VENTRICULAR FIBRILLATION OCCURRING DURING TREATMENT OF CHRONIC ATRIAL ARRHYTHMIAS.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970324-2

7 January 2021

Clinical predictors of arrhythmia worsening by antiarrhythmic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970324-2

7 January 2021

Safety of encainide for the treatment of ventricular arrhythmias

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970324-2

7 January 2021

Safety considerations and dosing guidelines for encainide in supraventricular arrhythmias

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970324-2

7 January 2021

Arrhythmogenic effects of antiarrhythmic drugs: a study of 506 patients treated for ventricular tachycardia or fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970324-2

7 January 2021

Aggravation of electrically provoked ventricular tachycardia during treatment with propafenone.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970324-2

7 January 2021

Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970324-2

7 January 2021

Aggravation and provocation of ventricular arrhythmias by antiarrhythmic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970324-2

7 January 2021

Malignant ventricular tachyarrhythmias associated with the use of encainide

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970324-2

7 January 2021

Pharmacologic causes of arrhythmogenic actions of antiarrhythmic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970324-2

7 January 2021

Identifiers

10.1016/S0025-7125(05)70324-2

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34172223&oldid=1976210027"